Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Neurimmune, Ono Expand Neurodegenerative Discovery Collaboration | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Neurimmune, Ono Expand Neurodegenerative Discovery Collaboration

Aims to generate and validate human-derived monoclonal antibodies against Ono's newly selected drug targets in the field of neurodegenerative diseases.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

p.p1 {margin: 0.0px 0.0px 8.0px 0.0px; font: 11.0px ‘Trebuchet MS’} span.s1 {letter-spacing: 0.0px}

Neurimmune AG has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. to create antibody drugs against new therapeutic targets in the field of neurodegenerative diseases using Neurimmune’s Reverse Translational Medicine (RTM) technology platform.

In November 2017, Ono and Neurimmune signed a drug discovery collaboration to identify and develop human antibodies using the RTM technology platform. Under the new collaboration, the companies aim to generate and validate human-derived monoclonal antibodies against Ono’s newly selected drug targets. Ono will obtain exclusive rights for worldwide development and commercialization of antibody products resulting from the collaboration. Ono will pay to Neurimmune an upfront payment, research fees, success-based R&D milestones, and royalties on product sales.

“We are excited to expand our long-term trusted partnership with Ono, a global pioneer of innovative medicines,” said Jan Grimm, CSO of Neurimmune. “The joint goal of the collaboration is to discover novel drug candidates for the treatment of neurodegenerative diseases using RTM technology.”

“We extremely appreciate Neurimmune’s RTM technology platform as an excellent antibody creation technology through our drug discovery projects.” said Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research of Ono Pharmaceutical. “Through this new collaboration, we will expand our central nervous system disease portfolio and work to deliver innovative medicines to patients with neurodegenerative diseases.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics